ArticleRevista Mocambicana de ciencias de saude2024
Article in Revista Mocambicana de ciencias de saude, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Introduction: Mozambique implements the prevention of mother-to-child transmission (PMTCT) of HIV as part of the national program since 2022. Despite the gains, vertical transmission rates continue high, estimated at 9% in 2023. We describe the progress of PMTCT in health facilities (HF) with PEPFAR support. Methods: We analyzed routine data of 656 HF with PEPFAR support, during the 2017 - 2023 fiscal years (October-September). We calculated the following proportions: pregnant women (PW) at first antenatal care consultation (ANC1) that knew their HIV status; HIV positive PW at ANC; PW on antiretroviral treatment (ART); PW on ART with a documented viral load (VL); PW with suppressed VL (VLS, defined as <1.000 copies/ml); HIV exposed children (HEI) tested up to 12 months, with a HIV positive result; HEI positive in ART. Data were analyzed by fiscal year (October - September). Results: During 2017-2023, the proportion of PW knowing their HIV status at ANC1 increased from 90,4% (863.181/954.933) to 99,9% (1.047.870/1.049.225); the proportion of PW on ART remained above 99%; the proportion of PW with VL test increased from 24,5% (9.862/40.293) to 74,9% (46.292/61.818); and the VLS increased from 51,4% (5.073/9.862) to 88,5% (40.950/46.292). During 2017-2023, HEI testing increased from 76,5% (64.322/84.038) to 96,0% (82.689/86.132), and testing positivity decreased from 8,5% (5.487/64.322) to 2,5% (2.075/82.689); during 2018-2023, the proportion of HIV positive HEI on ART increased from 82,7% (3.521/4.256) to 93,3% (1.936/2.075). Conclusions: Health facilities with PEPFAR support achieved progress in PMTCT. Continued implementation of sound interventions to improve ART initiation and retention, VLS and ART linkage of HEI testing HIV positive can lead to additional reduction of vertical transmission and its elimination as a public health problem in the country.
Indexed as
Identifiers
40123835PMC11926990What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.